Ipamorelin
Ipamorelin (NNC 26-0161; Aib-His-D-2-Nal-D-Phe-Lys-NH2)
Access and compounding status raise extra safety and legal questions.
A synthetic peptide that stimulates growth hormone release from the pituitary gland (a small gland in the brain) without significantly raising stress hormones or other unwanted hormones, giving it one of the mildest side-effect profiles among growth hormone-releasing peptides. It is not FDA-approved and is primarily available through compounding pharmacies.
This entry is a cited research summary, not an established treatment reference. Dosing language is included as source context, not as medical instruction.
Ipamorelin has limited human evidence; signal requires confirmation.
Access and compounding status raise extra safety and legal questions.
Safety Summary
In the Phase II postoperative ileus trial PMID 25331030, treatment-emergent adverse events were actually lower in the ipamorelin group (87.5%) than placebo (94.8%). No serious adverse events attributed to ipamorelin in any clinical trial. No significant elevations in cortisol, ACTH, or prolactin observed even at supraphysiologic doses (>200x ED50). Long-term safety data (>16 weeks) in humans are not available. Immunogenicity possible as with any synthetic peptide.
Clinical check-in
If real-world use or exposure is being considered, review potential interactions, contraindications, and monitoring needs with a licensed clinician rather than relying on summary copy alone.
Cited sources
Every claim on this page links to one of the 4 sources below. Identifiers are PubMed (PMID), ClinicalTrials.gov (NCT), or DOI; click through to the source of record before acting on a claim.
- 1PMID 9849822PubMed
- 2PMID 10496658PubMed
- 3PMID 25331030PubMed
- 4NCT01280344ClinicalTrials.gov